리서치사:Market Glass, Inc. (Formerly Global Industry Analysts, Inc.)
발행일:2024년 09월
페이지 정보:영문 246 Pages
라이선스 & 가격 (부가세 별도)
한글목차
RWE 솔루션 세계 시장은 2030년까지 44억 달러에 이를 전망
2023년에 17억 달러로 추정되는 RWE 솔루션 세계 시장은 2023-2030년간 CAGR 14.3%로 성장하여 2030년에는 44억 달러에 이를 것으로 예측됩니다. 본 보고서에서 분석한 부문 중 하나인 Real World Evidence Services는 CAGR 15.5%를 나타내고, 분석 기간 종료시에는 29억 달러에 이를 것으로 예측됩니다. al World Evidence Data Sets 분야의 성장률은 분석 기간중 CAGR 12.1%로 추정됩니다.
미국 시장은 4억 6,090만 달러로 추정, 중국은 CAGR13.3%로 성장 예측
미국 RWE 솔루션 시장은 2023년에 4억 6,090만 달러로 추정됩니다. 세계 2위 경제대국인 중국은 2030년까지 6억 5,260만 달러 규모에 이를 것으로 예측되어 분석 기간인 2023-2030년간 CAGR 은 13.3%입니다. 기타 주목해야 할 지역별 시장으로서는 일본과 캐나다가 있으며, 각각 분석 기간 중에 12.9%와 12.0%의 연평균 복합 성장률(CAGR)로 성장할 것으로 예측됩니다. 유럽에서는 독일이 CAGR 10.1%로 성장할 것으로 예측됩니다.
세계 리얼월드 에비던스 솔루션 시장 - 주요 동향 및 촉진요인 요약
RWE 솔루션: 데이터 기반 인사이트를 통한 헬스케어 혁신
/h3>
RWE(Real World Evidence) 솔루션은 업계 전반의 의사결정을 강화하는 데이터 기반 인사이트를 제공함으로써 헬스케어 산업을 변화시키고 있습니다.에 대한 임상적 증거를 말합니다. 이 데이터는 전자건강기록(EHR), 청구 데이터베이스, 환자 등록, 웨어러블 기기 등 다양한 출처에서 수집되며, 제약사, 규제 당국 및 의료 서비스 제공업체가 의약품 개발, 규제 승인 및 환자 치료 전략에 정보를 제공하기 위해 RWE를 활용하고 있습니다. 활용되고 있습니다. 통제된 조건에서 진행되는 기존 임상시험과 달리, RWE는 일상적인 임상 현장에서 치료가 어떻게 이루어지는지에 대한 통찰력을 제공하여 제품의 효과와 안전성을 보다 종합적으로 이해할 수 있도록 돕습니다. 이러한 접근방식은 특히 맞춤의료와 희귀질환에서 새로운 치료법의 가치를 입증하는 데 필수적인 역할을 하고 있습니다.
어떤 기술 발전이 RWE의 수집과 활용을 강화하는가?
기술의 발전으로 RWE의 수집, 분석 및 활용이 크게 향상되어 의료진에게 더욱 강력한 도구가 되고 있습니다. 빅데이터 분석, 인공지능(AI), 머신러닝(ML)을 RWE 플랫폼에 통합함으로써 방대한 양의 RWD를 처리하고 수작업으로는 감지할 수 없는 패턴과 통찰력을 발견할 수 있습니다. 또한, 데이터 통합 기술의 발전으로 다양한 소스의 데이터를 통합하여 환자의 결과를 전체적으로 파악할 수 있는 종합적인 데이터 세트를 생성할 수 있게 되었습니다. 또한, 자연어 처리(NLP)의 활용으로 의사의 메모나 소셜 미디어와 같은 비구조화된 소스에서 의미 있는 데이터를 추출할 수 있는 능력이 향상되고 있습니다. 이러한 기술 혁신은 RWE의 품질과 정확성을 향상시킬 뿐만 아니라, 의료 의사결정자들이 RWE를 보다 쉽고 실용적으로 사용할 수 있도록 돕고 있습니다.
건강관리에서 RWE의 주요 용도와 장점은 무엇인가?
RWE는 의료 분야의 광범위한 용도에 사용되어 환자 결과를 개선하고, 의료 효율성을 개선하며, 규제 결정을 지원하는 데 큰 이점을 제공합니다. 의약품 개발에서 RWE는 임상시험 데이터를 보완하는 데 사용되며, 다양한 인구 집단과 실제 환경에서 약물이 어떻게 작용하는지에 대한 통찰력을 제공하고 라벨링 및 시판 후 조사에 정보를 제공할 수 있습니다. 의료 서비스 제공업체는 RWE를 사용하여 특정 환자 집단에 가장 효과적인 치료법을 식별하고, 개인별 맞춤 의료 접근법을 지원하여 맞춤 치료법을 지원합니다. 지불자와 보험사는 RWE를 활용하여 치료의 비용 효율성을 평가하고, 상환 결정을 유도하며, 최대 가치를 제공하는 치료에 자원을 할당할 수 있도록 RWE의 주요 이점으로는 의료 제품의 실제 효과와 안전성에 대한 통찰력을 제공하고, 증거에 기반한 의사결정을 지원하며, 실제 환자 경험에 기반한 치료 전략을 알려줌으로써 환자의 치료 전략에 대한 정보를 제공하는 것 등이 있습니다. 실제 환자 경험에 기반한 치료 전략을 알려줌으로써 환자 치료를 개선할 수 있는 능력 등이 있습니다.
RWE 솔루션 시장의 성장을 가속하는 요인은 무엇일까?
RWE 솔루션 시장의 성장은 몇 가지 요인에 의해 촉진되고 있습니다. 헬스케어 이해관계자들이 확실한 근거를 바탕으로 정보에 입각한 의사결정을 내리고자 하는 가치 기반 의료에 대한 관심이 높아지면서 의료 제품의 실제 효능을 입증할 필요성이 높아진 것이 주요 촉진요인으로 작용하고 있습니다. 데이터 분석, AI, 디지털 헬스 플랫폼의 기술 발전은 RWE 솔루션의 기능과 접근성을 높여 시장 성장을 가속하고 있습니다. 개인 맞춤형 의료에 대한 수요 증가와 규제 당국의 승인을 지원하기 위한 데이터, 특히 희귀질환 및 복잡한 질환에 대한 데이터 필요성이 RWE에 대한 수요를 더욱 증가시키고 있습니다. 또한 EHR, 웨어러블 기기, 환자 보고 결과의 채택으로 디지털 건강 데이터의 가용성이 높아지면서 RWE 연구의 범위와 규모가 확대되고 있습니다. 이러한 요인들은 제약사, 의료 서비스 제공업체, 규제 기관 간의 협력 증가와 함께 리얼월드 에비던스 솔루션 시장의 지속적인 성장을 가속하고 있습니다.
조사 대상 기업 예(주목 46사)
Aetion
Cognizant Technology Solutions U.S. Corporation
IBM Corporation
Ignite Data Limited
IQVIA
PAREXEL International Corporation
PerkinElmer, Inc.
Pharmaceutical Product Development LLC
SAS Institute, Inc.
Syneos Health
목차
제1장 조사 방법
제2장 주요 요약
시장 개요
주요 기업
시장 동향과 촉진요인
세계 시장 전망
제3장 시장 분석
미국
캐나다
일본
중국
유럽
프랑스
독일
이탈리아
영국
기타 유럽
아시아태평양
기타 지역
제4장 경쟁
LSH
영문 목차
영문목차
Global Real World Evidence Solutions Market to Reach US$4.4 Billion by 2030
The global market for Real World Evidence Solutions estimated at US$1.7 Billion in the year 2023, is expected to reach US$4.4 Billion by 2030, growing at a CAGR of 14.3% over the analysis period 2023-2030. Real World Evidence Services, one of the segments analyzed in the report, is expected to record a 15.5% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Real World Evidence Data Sets segment is estimated at 12.1% CAGR over the analysis period.
The U.S. Market is Estimated at US$460.9 Million While China is Forecast to Grow at 13.3% CAGR
The Real World Evidence Solutions market in the U.S. is estimated at US$460.9 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$652.6 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 12.9% and 12.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.1% CAGR.
Global Real World Evidence Solutions Market - Key Trends and Drivers Summarized
Real World Evidence Solutions: Transforming Healthcare with Data-Driven Insights
Real World Evidence (RWE) solutions are transforming healthcare by providing data-driven insights that enhance decision-making across the industry. RWE refers to the clinical evidence regarding the usage and potential benefits or risks of a medical product derived from analysis of real-world data (RWD). This data is collected from various sources, including electronic health records (EHRs), claims databases, patient registries, and wearable devices. RWE is increasingly being used by pharmaceutical companies, regulators, and healthcare providers to inform drug development, regulatory approvals, and patient care strategies. Unlike traditional clinical trials, which are conducted under controlled conditions, RWE provides insights into how treatments perform in everyday clinical settings, offering a more comprehensive understanding of a product’s effectiveness and safety. This approach is becoming essential for demonstrating the value of new therapies, especially in personalized medicine and for rare diseases.
What Technological Advancements Are Enhancing the Collection and Utilization of RWE?
Technological advancements are significantly enhancing the collection, analysis, and utilization of RWE, making it a more powerful tool for healthcare stakeholders. The integration of big data analytics, artificial intelligence (AI), and machine learning (ML) into RWE platforms allows for the processing of vast amounts of RWD, uncovering patterns and insights that would be impossible to detect manually. Advances in data integration technologies are also enabling the aggregation of data from diverse sources, creating comprehensive datasets that provide a holistic view of patient outcomes. Moreover, the use of natural language processing (NLP) is improving the extraction of meaningful data from unstructured sources, such as physician notes and social media. These technological innovations are not only improving the quality and accuracy of RWE but are also making it more accessible and actionable for decision-makers in healthcare.
What Are the Key Applications and Benefits of RWE in Healthcare?
RWE is used in a wide range of applications in healthcare, offering significant benefits that enhance patient outcomes, improve healthcare efficiency, and support regulatory decision-making. In drug development, RWE is used to supplement clinical trial data, providing insights into how a drug performs across different populations and in real-world settings, which can inform labeling and post-market surveillance. Healthcare providers use RWE to identify the most effective treatments for specific patient populations, supporting personalized medicine approaches that tailor care to individual needs. Payers and insurers leverage RWE to assess the cost-effectiveness of treatments, guiding reimbursement decisions and ensuring that resources are allocated to therapies that offer the greatest value. The primary benefits of RWE include its ability to provide insights into the real-world effectiveness and safety of medical products, support evidence-based decision-making, and improve patient care by informing treatment strategies based on actual patient experiences.
What Factors Are Driving the Growth in the Real World Evidence Solutions Market?
The growth in the Real World Evidence Solutions market is driven by several factors. The increasing emphasis on value-based care and the need to demonstrate the real-world effectiveness of medical products are significant drivers, as healthcare stakeholders seek to make informed decisions based on robust evidence. Technological advancements in data analytics, AI, and digital health platforms are also propelling market growth by enhancing the capabilities and accessibility of RWE solutions. The rising demand for personalized medicine and the need for data to support regulatory approvals, particularly for rare diseases and complex conditions, are further boosting demand for RWE. Additionally, the growing availability of digital health data, driven by the adoption of EHRs, wearable devices, and patient-reported outcomes, is expanding the scope and scale of RWE studies. These factors, combined with increasing collaboration between pharmaceutical companies, healthcare providers, and regulatory bodies, are driving the sustained growth of the Real World Evidence Solutions market.
Select Competitors (Total 46 Featured) -
Aetion
Cognizant Technology Solutions U.S. Corporation
IBM Corporation
Ignite Data Limited
IQVIA
PAREXEL International Corporation
PerkinElmer, Inc.
Pharmaceutical Product Development LLC
SAS Institute, Inc.
Syneos Health
TABLE OF CONTENTS
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Global Economic Update
Real World Evidence Solutions - Global Key Competitors Percentage Market Share in 2024 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Demand for Evidence-Based Healthcare Propels Market Growth
Technological Advancements in Data Integration and Analytics Strengthen Market Position
Growing Focus on Personalized Medicine and Patient-Centric Care Drives Adoption of Real World Evidence Solutions
Surge in Demand for Post-Market Surveillance and Safety Monitoring Generates New Opportunities
Development of Advanced Data Collection and Management Platforms Sustains Market Growth
Expanding Applications in Drug Development and Clinical Trials Throws Spotlight on Market Potential
Rising Adoption of Real World Evidence in Payer Decision-Making and Reimbursement Processes Propels Market Expansion
Surge in Demand for Real-Time Data and Predictive Analytics Expands Market Horizons
Growing Awareness of the Benefits of Real World Evidence in Enhancing Treatment Outcomes Drives Market Adoption
Innovations in Artificial Intelligence and Machine Learning Generate New Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 2: World 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
TABLE 3: World Recent Past, Current & Future Analysis for Data Sets by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 4: World 7-Year Perspective for Data Sets by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Services by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 6: World 7-Year Perspective for Services by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 7: World Recent Past, Current & Future Analysis for Healthcare Payers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 8: World 7-Year Perspective for Healthcare Payers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 9: World Recent Past, Current & Future Analysis for Healthcare Providers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 10: World 7-Year Perspective for Healthcare Providers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 12: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
TABLE 13: World Real World Evidence Solutions Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 14: World Recent Past, Current & Future Analysis for Pharmaceutical & Medical Devices Companies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 15: World 7-Year Perspective for Pharmaceutical & Medical Devices Companies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
TABLE 16: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 17: USA 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 18: USA Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 19: USA 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
CANADA
TABLE 20: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 21: Canada 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 22: Canada Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 23: Canada 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
JAPAN
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
TABLE 24: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 25: Japan 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 26: Japan Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 27: Japan 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
CHINA
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
TABLE 28: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 29: China 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 30: China Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 31: China 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
EUROPE
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
TABLE 32: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
TABLE 33: Europe 7-Year Perspective for Real World Evidence Solutions by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
TABLE 34: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 35: Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 36: Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 37: Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
FRANCE
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
TABLE 38: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 39: France 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 40: France Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 41: France 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
GERMANY
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
TABLE 42: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 43: Germany 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 44: Germany Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 45: Germany 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
ITALY
TABLE 46: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 47: Italy 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 48: Italy Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 49: Italy 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
UNITED KINGDOM
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
TABLE 50: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 51: UK 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 52: UK Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 53: UK 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
REST OF EUROPE
TABLE 54: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 55: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 56: Rest of Europe Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 57: Rest of Europe 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
ASIA-PACIFIC
Real World Evidence Solutions Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
TABLE 58: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 59: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 60: Asia-Pacific Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 61: Asia-Pacific 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030
REST OF WORLD
TABLE 62: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by Component - Services and Data Sets - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 63: Rest of World 7-Year Perspective for Real World Evidence Solutions by Component - Percentage Breakdown of Value Sales for Services and Data Sets for the Years 2024 & 2030
TABLE 64: Rest of World Recent Past, Current & Future Analysis for Real World Evidence Solutions by End-Use - Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
TABLE 65: Rest of World 7-Year Perspective for Real World Evidence Solutions by End-Use - Percentage Breakdown of Value Sales for Pharmaceutical & Medical Devices Companies, Healthcare Payers, Healthcare Providers and Other End-Uses for the Years 2024 & 2030